meu31 Antibody

What is the primary antigen recognized by the BU31 monoclonal antibody?

The BU31 monoclonal antibody specifically recognizes nuclear lamins A and C. Through detailed immunoblotting studies using recombinant lamin proteins, researchers have conclusively identified these nuclear membrane proteins as the antigens recognized by BU31. This murine monoclonal antibody binds to the nuclear membrane of many cell types and demonstrates binding patterns that closely parallel the distribution of lamins A and C .

How does the expression pattern of BU31 antigen correlate with cellular proliferation?

The expression of the BU31 antigen exhibits an inverse correlation with the proliferative index in lung tumors, as defined by Ki67 staining. In various normal human and rat tissues, the distribution of BU31-positive cells parallels the distribution of non-dividing cells. Additionally, cells grown in culture that are induced to undergo growth arrest show significantly higher levels of labelling with BU31 compared to their proliferating counterparts. This relationship suggests that BU31 antigen expression is a potential marker for cellular quiescence .

What is the cellular distribution pattern of the BU31 antigen?

Confocal laser scanning microscopy reveals that the BU31 antigen is distributed predominantly along the nuclear lamina, with occasional internal foci observed. This distribution pattern is very similar to that of nuclear membrane proteins lamin A and lamin C, further confirming their identity as the target antigens of BU31. The characteristic distribution is valuable for researchers studying nuclear architecture and cellular quiescence .

How effective is MOC-31 as a diagnostic marker for metastatic adenocarcinoma?

MOC-31 has proven to be a highly effective diagnostic marker for metastatic adenocarcinoma in effusion specimens with impressive statistical performance:

These metrics indicate that MOC-31 is a reliable single immunomarker for distinguishing reactive mesothelial cells/mesothelioma from metastatic adenocarcinoma in effusion specimens .

What are the potential mechanisms underlying the role of nuclear lamins A and C in cellular quiescence?

The data from studies on BU31 antigen (identified as lamins A and C) suggest multiple potential mechanisms for how these nuclear lamins may function during cellular quiescence:

• Reorganization and maintenance of nuclear structure during the non-proliferative state

• Direct interactions with the retinoblastoma gene product (pRb)

• Interactions with pRb-related proteins

• Involvement in chromatin organization affecting gene expression patterns

These mechanisms could explain how nuclear lamins A and C contribute to maintaining the quiescent cellular state and regulating the proliferative capacity of both normal and neoplastic tissues .

How do you address discrepancies in MOC-31 staining patterns between different types of adenocarcinomas?

When encountering discrepancies in MOC-31 staining between different adenocarcinoma types, researchers should implement the following approach:

• Verify staining protocols using positive control specimens of known primary origin

• Pay particular attention to membrane staining patterns, as membranous staining with or without cytoplasmic staining is considered positive

• Acknowledge known detection limitations, particularly for specific primary sites that show reduced sensitivity:

  • Lung tumors (some cases show negative results)

  • Gastric tumors

  • Colorectal tumors

  • Breast tumors

  • Renal tumors

In cases with negative MOC-31 results but strong clinical suspicion of adenocarcinoma, additional markers should be employed in a panel approach to increase diagnostic accuracy .

What techniques can be used to investigate the relationship between RNA-binding proteins and membrane dynamics in cellular models?

Based on methodologies described in research on membrane dynamics, several approaches can be employed:

• Live-cell imaging techniques: Using fluorescently tagged membrane proteins (such as GFP-Psy1) to monitor membrane formation and dynamics over time

• Electron microscopy approaches:

  • Quick-freeze deep-etch replica electron microscopy to obtain high-contrast images of membrane structures

  • Thin-section electron microscopy with freeze-substitution technique to visualize membrane ultrastructure

• Western blotting: To detect protein expression levels and modifications using specific antibodies

• Reverse Transcription PCR: To analyze transcript levels of membrane-associated genes

• Gene knockout/mutation studies: To assess the functional importance of specific proteins in membrane dynamics

What is the recommended protocol for immunostaining effusion specimens with MOC-31?

The recommended protocol for MOC-31 immunostaining of effusion specimens includes:

• Sample preparation:

  • Process effusion fluid to prepare either cell blocks (preferred for archival purposes) or cytospin preparations

  • For cell blocks, use unstained sections

  • For cytospin preparations, use Papanicolaou-stained slides

• Immunostaining procedure:

  • Apply MOC-31 primary antibody at optimized dilution

  • Use appropriate detection system based on laboratory protocols

  • Include positive controls (confirmed adenocarcinoma) and negative controls (confirmed mesothelial cells)

• Interpretation criteria:

  • Consider membranous staining with or without cytoplasmic staining as positive

  • Be aware that minimal/focal cytoplasmic staining may be observed in approximately 13% of reactive mesothelial cells/mesothelioma (non-specific staining pattern)

  • Careful interpretation of staining patterns is essential to avoid misdiagnosis

How should the BU31 antibody be used to assess proliferative status in tissue samples?

When using BU31 antibody to assess proliferative status:

• Sample preparation:

  • Fix tissue samples appropriately to preserve nuclear membrane antigens

  • Prepare sections at optimal thickness (typically 3-5 μm)

• Dual immunostaining approach:

  • Perform sequential or simultaneous immunostaining with BU31 and Ki67

  • This allows direct comparison of the inverse relationship between BU31 antigen (lamins A/C) and proliferation

• Quantification methods:

  • Count BU31-positive and Ki67-positive cells in representative fields

  • Calculate the ratio of BU31-positive to Ki67-positive cells

  • Compare these ratios across different tissue regions or different samples

• Interpretation guidelines:

  • High BU31:Ki67 ratio indicates predominantly non-proliferating cell populations

  • Low BU31:Ki67 ratio suggests active proliferation

  • Some cell types (neuroendocrine cells, testicular germ cells) naturally show no reactivity with BU31 regardless of proliferative status

What approach should be used to investigate potential RNA-binding protein targets involved in membrane dynamics?

Based on methodologies used in related research, a systematic approach to investigate RNA-binding protein targets should include:

• RNA immunoprecipitation followed by sequencing (RIP-seq):

  • Use antibodies against the RNA-binding protein of interest

  • Identify bound transcripts through sequencing

  • Map the binding sites within target RNAs

• Gene expression profiling in wild-type and knockout models:

  • Compare transcript levels using RT-PCR or RNA-seq

  • Identify genes with altered expression levels in the absence of the RNA-binding protein

• Functional categorization of target transcripts:

  • Group identified targets by cellular function

  • Look for enrichment in specific pathways

• Validation of individual targets:

  • Generate knockout/knockdown models of identified targets

  • Assess phenotypic effects on membrane dynamics

  • Use fluorescence microscopy to visualize membrane changes

• Biochemical confirmation of direct binding:

  • Perform in vitro binding assays

  • Use electrophoretic mobility shift assays (EMSA)

  • Validate RNA recognition motifs through mutagenesis

How can researchers address issues of background staining when using nuclear membrane antibodies?

When troubleshooting background staining with nuclear membrane antibodies like BU31:

• Optimize blocking conditions:

  • Extend blocking time with appropriate blocking reagents

  • Consider using different blocking agents (BSA, normal serum, commercial blocking solutions)

  • Add detergents (like Tween-20) at appropriate concentrations to reduce non-specific binding

• Antibody dilution optimization:

  • Perform titration experiments to determine optimal antibody concentration

  • Too concentrated antibody solutions often lead to increased background

• Reduce autofluorescence (for fluorescent detection):

  • Use Sudan Black B treatment

  • Apply commercial autofluorescence quenchers

  • Consider tissue-specific autofluorescence countermeasures

• Modify washing protocols:

  • Increase number and duration of washing steps

  • Use appropriate buffers with optimized salt concentration and pH

• Control samples interpretation:

  • Always include negative controls (isotype controls, secondary-only controls)

  • Include positive controls with known expression patterns

  • Compare staining patterns with published literature to identify aberrant staining

What are the common pitfalls when interpreting MOC-31 immunostaining results in diagnostically challenging cases?

When interpreting MOC-31 immunostaining in challenging cases, researchers should be aware of these common pitfalls:

• Misinterpreting staining patterns:

  • Cytoplasmic-only staining may be non-specific

  • Membranous staining (with or without cytoplasmic component) is the critical positive pattern

  • Minimal/focal cytoplasmic staining can occur in reactive mesothelial cells (13% of cases)

• Primary tumor site limitations:

  • False negatives can occur in certain adenocarcinoma types (lung, stomach, colon, breast, renal)

  • Using MOC-31 alone may be insufficient for these tumor types

• Technical variables affecting results:

  • Suboptimal fixation can lead to false negative results

  • Antigen retrieval methods may impact sensitivity

  • Prolonged storage of unstained slides may reduce antigen detection

• Interpretation in context:

  • Always interpret MOC-31 results in conjunction with morphology

  • Consider a panel approach with complementary markers for challenging cases

  • Correlate results with clinical history and imaging findings

How do you reconcile contradictory findings when studying protein function using antibody-based detection versus genetic approaches?

When faced with contradictory findings between antibody-based and genetic approaches:

• Validate antibody specificity:

  • Test antibody reactivity in knockout/knockdown models

  • Perform Western blotting to confirm single-band detection at expected molecular weight

  • Consider using multiple antibodies targeting different epitopes of the same protein

• Assess genetic compensation mechanisms:

  • Knockout/mutation of a gene may trigger upregulation of related proteins

  • Acute depletion (e.g., RNAi) may show different phenotypes than constitutive knockout

  • Consider conditional knockouts or inducible systems to distinguish between developmental and direct effects

• Evaluate technical limitations of each approach:

  • Antibody detection may be affected by post-translational modifications

  • Genetic approaches may have off-target effects

  • Consider the timing of analysis (acute vs. chronic effects)

• Perform rescue experiments:

  • Re-introduce wild-type protein in knockout background

  • Use structure-function analysis with mutant versions

• Employ orthogonal techniques:

  • Mass spectrometry-based proteomics

  • In vitro functional assays

  • Live cell imaging with tagged proteins

What emerging technologies might enhance the specificity and sensitivity of antibody-based detection in complex tissue samples?

Several emerging technologies show promise for enhancing antibody-based detection in complex samples:

• Multiplexed immunofluorescence approaches:

  • Cyclic immunofluorescence (CycIF) for multiple marker detection on the same sample

  • Mass cytometry imaging (e.g., Imaging Mass Cytometry, MIBI-TOF) to detect dozens of markers simultaneously

• Spatial transcriptomics integration:

  • Combining antibody-based protein detection with spatial RNA analysis

  • Correlating protein expression with transcript levels at single-cell resolution

• AI-assisted image analysis:

  • Deep learning algorithms for automated pattern recognition

  • Reduction of interpreter bias and enhanced reproducibility

• Proximity ligation assays:

  • Detection of protein-protein interactions in situ

  • Enhanced specificity through dual-antibody recognition requirements

• CRISPR epitope tagging:

  • Endogenous tagging of proteins to eliminate antibody specificity issues

  • Combination with advanced microscopy for live cell studies

How might the understanding of nuclear membrane proteins inform new therapeutic strategies for cancer?

Understanding nuclear membrane proteins like lamins A and C (BU31 antigens) could inform novel therapeutic strategies:

• Targeting quiescence mechanisms:

  • Development of therapies that disrupt interactions between lamins and cell cycle regulators

  • Forcing quiescent cancer cells to re-enter the cell cycle, increasing vulnerability to chemotherapy

• Nuclear structure modulation:

  • Compounds that affect nuclear lamina integrity may selectively target cancer cells with altered nuclear morphology

  • Exploiting differences in nuclear mechanics between normal and cancer cells

• Biomarker-driven therapeutic strategies:

  • Using nuclear membrane protein expression patterns to stratify patients for specific treatments

  • Monitoring changes in lamin expression as indicators of treatment response

• Immunotherapy approaches:

  • Development of antibody-drug conjugates targeting cancer-specific nuclear membrane aberrations

  • CAR-T or other cellular therapies recognizing cancer-specific nuclear protein presentations

• Lamin-directed gene therapy:

  • Exploiting lamin interactions with chromatin to target therapeutic gene expression to specific cellular states

  • Using lamin promoters to drive therapeutic gene expression selectively in quiescent or proliferating cells

What research questions remain unresolved regarding the relationship between RNA-binding proteins and membrane dynamics?

Several unresolved questions merit further investigation:

• Temporal dynamics:

  • How do RNA-binding proteins coordinate the timing of membrane-related gene expression?

  • What are the kinetics of membrane protein synthesis, trafficking, and turnover regulated by RNA-binding proteins?

• Compartmentalization:

  • How do RNA-binding proteins contribute to localized translation near membrane structures?

  • What mechanisms target specific mRNAs to distinct subcellular domains?

• Regulatory networks:

  • How do multiple RNA-binding proteins function in coordinated networks to regulate membrane dynamics?

  • What are the hierarchical relationships between different RNA regulators?

• Post-transcriptional modifications:

  • How do modifications of mRNAs (m6A, m5C, etc.) affect their regulation by RNA-binding proteins?

  • What enzymes mediate these modifications in membrane-associated transcripts?

• Therapeutic potential:

  • Can targeting specific RNA-binding proteins modify membrane dynamics in disease states?

  • What small molecules might modulate RNA-binding protein functions with therapeutic benefit?